AIMS: Spindle-cell/sclerosing rhabdomyosarcomas (SS-RMS) are clinically and genetically heterogeneous. They include three well-defined molecular subtypes, of which those with EWSR1/FUS::TFCP2 rearrangements were described only recently. This study aimed to evaluate five new cases of SS-RMS and to perform a clinicopathological and statistical analysis of all TFCP2-rearranged SS-RMS described in the English literature to more comprehensively characterize this rare tumour type. METHODS AND RESULTS: Cases were retrospectively selected and studied by immunohistochemistry, fluorescence in situ hybridization with EWSR1/FUS and TFCP2 break-apart probes, next-generation sequencing (Archer FusionPlex Sarcoma kit and TruSight RNA Pan-Cancer Panel). The PubMed database was searched for relevant peer-reviewed English reports. Five cases of SS-RMS were found. Three cases were TFCP2 rearranged SS-RMS, having FUSex6::TFCP2ex2 gene fusion in two cases and triple gene fusion EWSR1ex5::TFCP2ex2, VAX2ex2::ALKex2 and VAX2intron2::ALKex2 in one case. Two cases showed rhabdomyoblastic differentiation and spindle-round cell/sclerosing morphology, but were characterized by novel genetic fusions including EWSR1ex8::ZBTB41ex7 and PLOD2ex8::RBM6ex7, respectively. In the statistical analysis of all published cases, CDKN2A or ALK alterations, the use of standard chemotherapy and age at presentation in the range of 18-24 years were negatively correlated to overall survival. CONCLUSION: EWSR1/FUS::TFCP2-rearranged SS-RMS is a rare rhabdomyosarcoma subtype, affecting predominantly young adults with average age at presentation 34 years (median 29.5 years; age range 7-86 years), with a predilection for craniofacial bones, rapid clinical course with frequent bone and lung metastases, and poor prognosis (3-year overall survival rate 28%).

Bioptic Laboratory Ltd Plzen Czech Republic

Cytopathos Ltd Bratislava Slovakia

Department of Pathology Faculty of Medicine in Plzen Charles University Prague Czech Republic

Department of Pathology Třinec Hospital Třinec Czech Republic

Division of Information Technologies and Statistics Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Medical Laboratory CSD Kyiv Ukraine

Medicyt Ltd Košice Slovakia

Onco Team Diagnostic București Romania

Unilabs Diagnostic Pathology Centre Prešov Slovakia

Zobrazit více v PubMed

Rekhi B, Gupta C, Chinnaswamy G et al. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: a single institutional experience. Ann. Diagn. Pathol. 2018; 36; 50-60.

Weiel JJ, Kokh D, Charville GW, Longacre TA. PAX7 is a sensitive marker of skeletal muscle differentiation in rhabdomyosarcoma and tumors with Rhabdomyosarcomatous differentiation in the female genital tract. Int. J. Gynecol. Pathol. 2022; 41; 235-243.

WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. In WHO classification of tumours series. Vol. 3. 5th ed. Lyon, France: International Agency for Research on Cancer, 2020. https://publications.iarc.fr/588

Agaram NP, Szuhai K. Spindle cell/sclerosing rhabdomyosarcoma. In WHO classification of Tumours editorial board soft tissue and bone tumors. 5th ed. Lyon: International Agency for Research on Cancer., vol 3. WHO classification of tumours series, 211-213, 2020. https://publicationsiarcfr/588.

Cavazzana AO, Schmidt D, Ninfo V et al. Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am. J. Surg. Pathol. 1992; 16; 229-235.

WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. (WHO classification of tumours series, 5th ed, vol. 3). Lyon: International Agency for Research on Cancer, 2020. https://publications.iarc.fr/588.

Mosquera JM, Sboner A, Zhang L et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 2013; 52; 538-550.

Alaggio R, Zhang L, Sung YS et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am. J. Surg. Pathol. 2016; 40; 224-235.

Szuhai K, de Jong D, Leung WY, Fletcher CDM, Hogendoorn PCW. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J. Pathol. 2014; 232; 300-307.

Kohsaka S, Shukla N, Ameur N et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat. Genet. 2014; 46; 595-600.

Agaram NP, Chen CL, Zhang L, LaQuaglia MP, Wexler L, Antonescu CR. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes Cancer 2014; 53; 779-787.

Agaram NP, LaQuaglia MP, Alaggio R et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod. Pathol. 2019; 32; 27-36.

Watson S, Perrin V, Guillemot D et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J. Pathol. 2018; 245; 29-40.

Dashti NK, Wehrs RN, Thomas BC et al. Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype. Histopathology 2018; 73; 514-520.

Le Loarer F, Cleven AHG, Bouvier C et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod. Pathol. 2020; 33; 404-419.

Han R, Dermawan JK, Demicco EG et al. ZFP64::NCOA3 gene fusion defines a novel subset of spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 2022; 61; 645-652.

Agaimy A, Dermawan JK, Leong I et al. Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck. Genes Chromosomes Cancer 2022; 61; 701-709.

Yoshida KI, Kukita Y, Nakamura H, Nakai S, Honma K, Yagi T. A case of spindle cell rhabdomyosarcoma with an EP300::VGLL3 fusion. Genes Chromosomes Cancer 2023; 62; 184-186.

Dehner CA, Broski SM, Meis JM et al. Fusion-driven spindle cell rhabdomyosarcomas of bone and soft tissue: a clinicopathologic and molecular genetic study of 25 cases. Mod. Pathol. 2023; 36; 100271. https://doi.org/10.1016/j.modpat.2023.100271

Skalova A, Ptakova N, Santana T et al. NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is "Intraductal" correct? Am. J. Surg. Pathol. 2019; 43; 1303-1313.

https://www.illumina.com/content/dam/illumina-marketing/documents/products/gene_lists/gene_list_trusight_oncology_500.xlsx.

https://emea.support.illumina.com/content/dam/illumina-support/documents/downloads/productfiles/trusight/trusight-rna-pan-cancer-target-regions-gtf.zip.

Skalova A, Baneckova M, Laco J et al. Sclerosing polycystic adenoma of salivary glands: a novel neoplasm characterized by PI3K-AKT pathway alterations-new insights into a challenging entity. Am. J. Surg. Pathol. 2022; 46; 268-280.

Skalova A, Agaimy A, Vanecek T et al. Molecular profiling of clear cell myoepithelial carcinoma of salivary glands with EWSR1 rearrangement identifies frequent PLAG1 gene fusions but no EWSR1 fusion transcripts. Am. J. Surg. Pathol. 2021; 45; 1-13.

Agaram NP, Zhang L, Sung YS et al. Expanding the spectrum of intraosseous rhabdomyosarcoma: correlation between 2 distinct gene fusions and phenotype. Am. J. Surg. Pathol. 2019; 43; 695-702.

Lewin J, Desai J, Smith K, Luen S, Wong D. Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression. Pathology 2019; 51; 655-657.

Tagami Y, Sugita S, Kubo T et al. Spindle cell rhabdomyosarcoma in a lumbar vertebra with FUS-TFCP2 fusion. Pathol. Res. Pract. 2019; 215; 152399.

Chrisinger JSA, Wehrli B, Dickson BC et al. Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases. Virchows Arch. 2020; 477; 725-732.

Brunac AC, Laprie A, Castex MP et al. The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript. Pediatr. Blood Cancer 2020; 67; e28185.

Koutlas IG, Olson DR, Rawwas J. FET(EWSR1)-TFCP2 rhabdomyosarcoma: an additional example of this aggressive variant with predilection for the gnathic bones. Head Neck Pathol. 2021; 15; 374-380.

Xu B, Suurmeijer AJH, Agaram NP, Zhang L, Antonescu CR. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology 2021; 79; 347-357.

Ochsner AR, Foss RD. Epithelioid and spindle cell rhabdomyosarcoma of the oral mucosa with FUS rearrangement. Head Neck Pathol. 2022; 16; 823-827.

Panferova A, Sinichenkova KY, Abu Jabal M et al. EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas. Cold Spring Harb. Mol. Case Stud. 2022; 8; 8.

Silva Cunha JL, Cavalcante IL, da Silva Barros CC et al. Intraosseous rhabdomyosarcoma of the maxilla with TFCP2 fusion: a rare aggressive subtype with predilection for the gnathic bones. Oral Oncol. 2022; 130; 105876.

Ishiyama T, Kato I, Ito J et al. Rhabdomyosarcoma with FUS::TFCP2 fusion in the scalp: a rare case report depicting round and spindle cell morphology. Int. J. Surg. Pathol. 2023; 31; 805-812.

Valerio E, Furtado Costa JL, Perez Fraile NM et al. Intraosseous spindle cell/epithelioid rhabdomyosarcoma with TFCP2 rearrangement: a recent recognized subtype with partial response to Alectinib. Int. J. Surg. Pathol. 2023; 31; 861-865.

Gallagher KPD, Roza A, Tager E et al. Rhabdomyosarcoma with TFCP2 rearrangement or typical co-expression of AE1/AE3 and ALK: report of three new cases in the head and neck region and literature review. Head Neck Pathol. 2022; 17; 546-561.

Ma Y, Feng J, Ding D, Zhao J, Tian F. TFCP2-rearranged epithelioid and spindle cell rhabdomyosarcoma in the bladder: a rare case in an 8-year-old female child. Pediatr. Blood Cancer 2023; 70; e29935.

Duan FL, Yang H, Gong X et al. Clinicopathological features of rhabdomyosarcoma with novel FET::TFCP2 and TIMP3::ALK fusion: report of two cases and literature review. Histopathology 2023; 82; 478-484.

Carrillo-Ng H, Liang Y, Chang S et al. Complete mimicry: rhabdomyosarcoma with FUS::TFCP2 fusion masquerading as carcinoma-diagnostic challenge and report of two cases. Genes Chromosomes Cancer 2023; 62; 430-436.

Wong DD, van Vliet C, Gaman A, Giardina T, Amanuel B. Rhabdomyosarcoma with FUS re-arrangement: additional case in support of a novel subtype. Pathology 2019; 51; 116-120.

Cyrta J, Gauthier A, Karanian M et al. Infantile rhabdomyosarcomas with VGLL2 rearrangement are not always an indolent disease: a study of 4 aggressive cases with clinical, pathologic, molecular, and radiologic findings. Am. J. Surg. Pathol. 2021; 45; 854-867.

Van Antwerp ME, Chen DG, Chang C et al. A point mutation in the MyoD basic domain imparts c-Myc-like properties. Proc. Natl. Acad. Sci. U. S. A. 1992; 89; 9010-9014.

Yoo BK, Emdad L, Gredler R et al. Transcription factor late SV40 factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2010; 107; 8357-8362.

Kotarba G, Krzywinska E, Grabowska AI, Taracha A, Wilanowski T. TFCP2/TFCP2L1/UBP1 transcription factors in cancer. Cancer Lett. 2018; 420; 72-79.

Taracha A, Kotarba G, Wilanowski T. Neglected functions of TFCP2/TFCP2L1/UBP1 transcription factors may offer valuable insights into their mechanisms of action. Int. J. Mol. Sci. 2018; 19; 2852. https://doi.org/10.3390/ijms19102852

Sun Y, Nowak KA, Zaorsky NG et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Mol. Cancer Ther. 2013; 12; 696-704.

Dai Y, Wei Q, Schwager C et al. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Radiother. Oncol. 2015; 114; 173-181.

Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr. Probl. Cancer 2021; 45; 100768.

Theilen TM, Soerensen J, Bochennek K et al. Crizotinib in ALK(+) inflammatory myofibroblastic tumors-current experience and future perspectives. Pediatr. Blood Cancer 2018; 65. https://doi.org/10.1002/pbc.26920

Chelsky ZL, Paulson VA, Chen EY. Molecular analysis of 10 pleomorphic rhabdomyosarcomas reveals potential prognostic markers and druggable targets. Genes Chromosomes Cancer 2022; 61; 138-147.

Perez M, Munoz-Galvan S, Jimenez-Garcia MP et al. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget 2015; 6; 40557-40574.

Weber A, Marquardt J, Elzi D et al. Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J. 2008; 27; 1563-1574.

Roussel-Gervais A, Naciri I, Kirsh O et al. Loss of the methyl-CpG-binding protein ZBTB4 alters mitotic checkpoint, increases aneuploidy, and promotes tumorigenesis. Cancer Res. 2017; 77; 62-73.

Yu Y, Shang R, Chen Y et al. Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. Biomed. Pharmacother. 2018; 100; 108-115.

Kim K, Chadalapaka G, Pathi SS et al. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol. Cancer Ther. 2012; 11; 1852-1862.

Sutherland LC, Rintala-Maki ND, White RD, Morin CD. RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J. Cell. Biochem. 2005; 94; 5-24.

Machour FE, Abu-Zhayia ER, Awwad SW et al. RBM6 splicing factor promotes homologous recombination repair of double-strand breaks and modulates sensitivity to chemotherapeutic drugs. Nucleic Acids Res. 2021; 49; 11708-11727.

Tong Y, Qi Y, Xiong G et al. The PLOD2/succinate axis regulates the epithelial-mesenchymal plasticity and cancer cell stemness. Proc. Natl. Acad. Sci. U. S. A. 2023; 120; e2214942120.